ACLX Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of 39.21%. Arcellx, Inc.'s return on equity of -49.8% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Arcellx, Inc. has a consensus price target of $112.35, signalling upside risk potential of 69.54%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $134.22 which suggests that it could grow by 10.84%. Given that Arcellx, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Arcellx, Inc. is more attractive than Gilead Sciences, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.568%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.61% to investors and pays a quarterly dividend of $0.79 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Arcellx, Inc.'s net income of -$55.8M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 102.62x versus 5.24x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Invivyd, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of -79.75%. Arcellx, Inc.'s return on equity of -49.8% beat Invivyd, Inc.'s return on equity of -87.85%.

Arcellx, Inc. has a consensus price target of $112.35, signalling upside risk potential of 69.54%. On the other hand Invivyd, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 296.83%. Given that Invivyd, Inc. has higher upside potential than Arcellx, Inc., analysts believe Invivyd, Inc. is more attractive than Arcellx, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invivyd, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invivyd, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Invivyd, Inc. pays out -- of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Invivyd, Inc. quarterly revenues of $13.1M. Arcellx, Inc.'s net income of -$55.8M is lower than Invivyd, Inc.'s net income of -$10.5M. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Invivyd, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 102.62x versus 6.67x for Invivyd, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of 21.47%. Arcellx, Inc.'s return on equity of -49.8% beat Johnson & Johnson's return on equity of 33.27%.

Arcellx, Inc. has a consensus price target of $112.35, signalling upside risk potential of 69.54%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could grow by 3.72%. Given that Arcellx, Inc. has higher upside potential than Johnson & Johnson, analysts believe Arcellx, Inc. is more attractive than Johnson & Johnson.

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.52% to investors and pays a quarterly dividend of $1.30 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Arcellx, Inc.'s net income of -$55.8M is lower than Johnson & Johnson's net income of $5.2B. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 19.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 102.62x versus 5.38x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Relmada Therapeutics, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of --. Arcellx, Inc.'s return on equity of -49.8% beat Relmada Therapeutics, Inc.'s return on equity of -214.4%.

Arcellx, Inc. has a consensus price target of $112.35, signalling upside risk potential of 69.54%. On the other hand Relmada Therapeutics, Inc. has an analysts' consensus of $6.67 which suggests that it could grow by 54.68%. Given that Arcellx, Inc. has higher upside potential than Relmada Therapeutics, Inc., analysts believe Arcellx, Inc. is more attractive than Relmada Therapeutics, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Relmada Therapeutics, Inc. has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.834%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Relmada Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are larger than Relmada Therapeutics, Inc. quarterly revenues of --. Arcellx, Inc.'s net income of -$55.8M is lower than Relmada Therapeutics, Inc.'s net income of -$10.1M. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Relmada Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 102.62x versus -- for Relmada Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.